97233 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies; Hybrid immunoglobulins; Igs containing Ig-regions, -domains or -residues form different species Igs containing CDR-residues from one specie grafted between FR-residues from another
Sub-classes:ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE
#2METHODS AND COMPOSITIONS FOR TREATING STAPHYLOCOCCAL INFECTIONS
#3ANTIBODY AND USE THEREOF
#4DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10
#5METHOD FOR HUMANIZING ANTIBODIES
#6ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE
#7RECOMBINANT GENOME, AND NON-HUMAN MAMMALIAN CELL AND PRODUCTION METHOD THEREFOR AND USE THEREOF
#8VISTA ANTIGEN-BINDING MOLECULES
#9RECOMBINANT GENOME, AND NON-HUMAN MAMMALIAN CELL AND PRODUCTION METHOD THEREFOR AND USE THEREOF
#10Dual cytokine fusion proteins comprising IL-10
#11Dual cytokine fusion proteins comprising IL-10
#12Dual cytokine fusion proteins comprising IL-10
#13Dual cytokine fusion proteins comprising IL-10
#14Dual cytokine fusion proteins comprising IL-10
#15Dual cytokine fusion proteins comprising IL-10
#16Dual cytokine fusion proteins comprising IL-10
#17Dual cytokine fusion proteins comprising IL-10
#18Dual cytokine fusion proteins comprising IL-10
#19Dual cytokine fusion proteins comprising IL-10
#20PRODRUGGABLE ANTIBODIES, PRODRUGS THEREOF, AND METHODS OF USE AND MAKING
#21HUMANIZED ANTIBODIES WITH ULTRALONG COMPLEMENTARY DETERMINING REGIONS
#22NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
#23Antibody and use thereof
#24METHODS AND COMPOSITIONS FOR TREATING STAPHYLOCOCCAL INFECTIONS
#25Dual cytokine fusion proteins comprising IL-10
#26Dual cytokine fusion proteins comprising IL-10
#27ANTI-CEACAM5 ANTIBODIES AND USES THEREOF
#28Dual cytokine fusion proteins comprising IL-10
#29EXPRESS HUMANIZATION OF ANTIBODIES
#30Dual cytokine fusion proteins comprising IL-10
#31Dual cytokine fusion proteins comprising IL-10
#32Dual cytokine fusion proteins comprising IL-10
#33Dual cytokine fusion proteins comprising IL-10
#34Method for controlling affinity of antibody for antigen, antibody whose affinity for antigen has been altered, and its production method
#35T cell activating bispecific antigen binding molecules
#36Novel Methionine Containing Antibodies for Conjugation of Agents
#37Dual cytokine fusion proteins comprising IL-10
#38METHOD FOR PRODUCING POLYPEPTIDE HETERO-OLIGOMER
#39METHOD FOR MASS HUMANIZATION OF NON-HUMAN ANTIBODIES
#40BIOLOGICAL PRODUCTS
#41ANTIBODY FRAMEWORKS FOR REDUCING AGGREGATION OF MULTISPECIFIC ANTIBODIES
#42Isoform-selective anti-TGFβ antibodies and methods of use
#43ANTI-SAS1B ANTIBODIES, ASSOCIATED METHODS OF USE, AND COMPOSITIONS AND METHODS FOR DETECTING AND TREATING CANCER
#44N-Glycosylation
#45N-Glycosylation
#46N-Glycosylation
#47Acceptor Framework for CDR Grafting
#48Compositions and methods for treating IgE-mediated disorders
#49TfR selective binding compounds and related methods
#50VISTA antigen-binding molecules
#51Humanized antibodies with ultralong complementary determining regions
#52Three-dimensional structure-based humanization method
#53COMMON LIGHT CHAINS AND METHODS OF USE
#54Express humanization of antibodies
#55Monoclonal and humanized antibodies to a cancer glycopeptide
#56Compounds binding human CD160 and uses thereof
#57Anti-CEACAM5 antibodies and uses thereof
#58THROMBIN ANTIBODY, ANTIGEN-BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF
#59Anti-CD3 epsilon antibodies and methods of use thereof
#60Method for mass humanization of non-human antibodies
#61Antibodies with low immunogenicity and uses thereof
#62ANTI-SAS1B ANTIBODIES, ASSOCIATED METHODS OF USE, AND COMPOSITIONS AND METHODS FOR DETECTING AND TREATING CANCER
#63Cytosol-penetrating antibody and use thereof
#64Binding domain or antibody specific to a human serum albumin (HSA)
#65Prodruggable antibodies, prodrugs thereof, and methods of use and making
#66Polypeptide selectively binding to immunoglobulin G of mouse or rabbit and use thereof
#67Method for controlling affinity of antibody for antigen, antibody whose affinity for antigen has been altered, and its production method
#68CA6 Antigen-Specific Cytotoxic Conjugate and Methods of Using the Same
#69Anti-c-Met antibody and anti-c-Met antibody-cytotoxic drug conjugate and pharmaceutical use thereof
#70Method for producing polypeptide hetero-oligomer
#71Anti-CEACAM5 antibodies and uses thereof
#72N-glycosylation
#73TfR selective binding compounds and related methods
#74NOVEL COMPOSITIONS AND METHODS FOR TREATING IgE-MEDIATED DISORDERS
#75NEUTRALISING ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN IL-17
#76COMMON LIGHT CHAINS AND METHODS OF USE
#77Express humanization of antibodies
#78BIOLOGICAL PRODUCTS
#79Method for mass humanization of non-human antibodies
#80ANTIBODIES TO RECEPTOR OF ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF
#81Anti-EphA2 antibodies and methods of use thereof
#82Amino acid sequences directed against the angiopoietin/tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
#83CA6 antigen-specific cytotoxic conjugate and methods of using the same
#84Acceptor framework for CDR grafting
#85ACCEPTOR FRAMEWORK FOR CDR GRAFTING
#86Binding Moieties Based On Shark IgNAR Domains
#87Monoclonal anti-GT 468 antibodies for treatment of cancer
#88Humanized antibodies with ultralong complementary determining regions
#89Anti-CEACAM5 antibodies and uses thereof
#90Immunoglobulin variable region cassette exchange
#91HUMANIZED ANTIBODIES SPECIFIC FOR STAPHYLOCOCCAL ENTEROTOXIN B
#92Anti-EphA2 antibodies and methods of use thereof
#93Acceptor framework for CDR grafting
#94Acceptor framework for CDR grafting
#95Method of treating cancer by administering a monoclonal antibody that binds human NOTCH2 and NOTCH3
#96Methods of treating GVHD and transplant rejection with anti-PSGL-1 antibodies
#97Notch1 receptor binding agents and methods of use thereof
#98Compositions and methods for treating IgE-mediated disorders
#99Compositions and methods for treating IgE-mediated disorders
#100Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
#101Human tissue factor antibody and uses thereof
#102ANTIBODY CONSTANT DOMAIN REGIONS AND USES THEREOF
#103HUMANIZED ANTIBODY AND PROCESS FOR PREPARING SAME
#104Polynucleotides encoding NOTCH1 receptor antibodies
#105Express humanization of antibodies
#106Monoclonal antibody that binds human notch2 and notch3
#107Notch1 receptor antibodies and methods of treatment
#108Humanized antibodies with anti-tumor activity
#109Polynucleotides encoding Notch receptor antibodies
#110Neutralising antibody molecules having specificity for human IL-17
#111Anti-tumor antigen antibodies and methods of use
#112Compositions and methods for treating IgE-mediated disorders
#113Compositions and methods for treating IgE-mediated disorders
#114Human tissue factor antibody and uses thereof
#115Canine thymic stromal lymphopoietin protein and uses thereof to treat allergic symptoms
#116Compositions and methods for treating IgE-mediated disorders
#117Acceptor framework for CDR grafting
#118Acceptor framework for CDR grafting
#119Immunobinders directed against TNF
#120ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATMENT OF INFLAMMATORY CONDITIONS
#121Anti-PSGL-1 antibodies
#122Anti-PSGL-1 antibodies and methods of inducing cell death of an activated T cell
#123Antibodies with enhanced or suppressed effector function
#124Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#125Monoclonal antibodies for treatment of cancer
#126BIOLOGICAL PRODUCTS
#127Methods of treatment by administering antibodies to notch receptors
#128Human tissue factor antibody and uses thereof
#129Methods of monitoring a human anti-human antibody response and inhibitors thereof
#130Humanized antibodies against human interferon-alpha
#131Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#132Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
#133Nucleic acid molecules encoding neutralising antibodies having specificity for human IL-17
#134Binding Moieties Based On Shark IgNAR Domains
#135NOTCH1 receptor antibodies and methods of treatment
#136CDR-repaired antibodies
#137Hybrid antibodies
#138ANTI-CD137 ANTIBODY AS AN AGENT IN THE TREATMENT OF INFLAMMATORY CONDITIONS
#139Humanized antibodies against human interferon-alpha
#140Anti-PSGL-1 antibodies
#141Biological products
#142SUPER HUMANIZED ANTIBODIES
#143CA6 antigen-specific cytotoxic conjugate and methods of using the same
#144Fusion proteins comprising canine thymic stromal lymphopoietin protein and uses thereof
#145Hybrid antibodies
#146Antibody constant domain regions and uses thereof
#147Humanised antibodies with anti-tumour activity
#148BINDING CONSTRUCTS AND METHODS FOR USE THEREOF
#149Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#150Framework-Shuffling Of Antibodies
#151FUNCTIONAL HUMANIZATION OF COMPLEMENTARITY DETERMINING REGIONS (CDRS)
#152ANTI-EGFR ANTIBODIES
#153Antibodies to notch receptors
#154Compositions and methods for treating IgE-mediated disorders
#155Hybrid antibodies
#156Reducing the risk of human anti-human antibodies through V gene manipulation
#157Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
#158Biological products
#159Framework selection
#160Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
#161Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#162METHODS OF OPTIMIZING ANTIBODY VARIABLE REGION BINDING AFFINITY
#163ANTI-PSGL-1 ANTIBODIES
#164BINDING CONSTRUCTS AND METHODS FOR USE THEREOF
#165Methods of inducing cell death of an activated T cell with anti-PSGL-1 antibodies
#166Binding moieties based on shark ignar domains
#167Methods for use in human-adapting monoclonal antibodies
#168Neutralising antibody molecules having specificity for human IL-17
#169CA6 antigen-specific cytotoxic conjugate and methods of using the same
#170Anti-TNFα antibodies and methods of use
#171Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#172Anti-EGFR antibodies
#173Canine thymic stromal lymphopoietin protein and uses thereof
#174Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
#175Binding constructs and methods for use thereof
#176Anti-TNFα antibodies
#177Biological products
#178CA6 antigen-specific cytotoxic conjugate and methods of using the same
#179Humanized antibody and process for preparing same
#180Method of humanizing antibodies by matching canonical structure types CDRs
#181Framework-shuffling of antibodies
#182Immunoglobulin variable region cassette exchange
#183CDR-repaired antibodies
#184Humanized antibodies against the venezuelan equine encephalitis virus
#185Determining the risk of human anti-human antibodies in transgenic mice
#186Natural humanized antibody
#187Anti-PSGL-1 antibodies
#188Super humanized antibodies
#189Reducing the risk of human anti-human antibodies through V gene manipulation
#190Protein engineering with analogous contact environments
#191Binding constructs and methods for use thereof
#192Heteromeric variable regions with unvaried human framework regions
#193Biosynthetic binding proteins for immuno-targeting
#194Vista antigen-binding molecules